SSI Diagnostica Group acquires Gulf Coast Scientific

SSI Diagnostica Group acquires Gulf Coast Scientific – the Florida-based IVD company specialized in Urea Breath Testing for Helicobacter Pylori and further strengthens the Group’s footprint in the US clinical diagnostic market.

SSI Diagnostica Group, a global leading developer and manufacturer of specialized infectious disease diagnostic solutions, is acquiring Gulf Coast Scientific (GCS) located in Florida, USA to further strengthen its gastrointestinal disease testing portfolio.

SSI Diagnostica Group focuses on infectious disease in-vitro diagnostic solutions and antisera and other reagent development for gastric, respiratory and bloodborne diseases. Headquartered in Denmark, the company sells its products in 100 countries worldwide, with direct sales in the Nordics and the USA. It has US locations in California and Virginia with strong R&D capabilities, product development, and state-of-the-art manufacturing from which it serves leading US reference laboratories and hospital labs. GCS specializes in the development of Urea Breath Testing for Helicobacter Pylori (H. Pylori) – a gastric bacteria infecting more than 60 million people annually in the USA alone. The bacteria causes chronic gastritis, gastric cancer, and other cardiovascular and metabolic conditions – diseases critical to detect and treat early at onset to help people live healthier lives.

Acquiring Gulf Coast Scientific complements the company’s gastric portfolio – allowing SSI Diagnostica Group to support its reference and hospital lab customers in the USA and beyond with a broader range of highly specialized products. Jointly, the group will have a total revenue of 850 mDKK (~125 mUSD), growing faster than the market. The company will consist of nearly 600 talented employees across sites in Denmark, the US and China.

Nachum (Homi) Shamir, Chairman of the board, states: “This acquisition demonstrates the potential and capabilities of the SSI Diagnostica Group. It shows our commitment to continue to invest and build our company. Our goal for the next few years is to rapidly grow SSID Group organically and through acquisitions. The USA is a key market, and we are excited to strengthen our position further with additional synergistic quality products in a new technological area.”

The acquisition strengthens the group’s range and technologies for detecting gastric bacterial diseases. Combining the portfolio of Urea Breath Testing and Rapid Solutions for H. Pylori whilst also offering a strong range of testing for other gastric diseases, e.g. C. Difficile, Lactoferrin and other Foodborne Diseases, makes SSI Diagnostica Group able to offer critical diagnostic solutions for patients with similar symptoms – but with unique urgent treatment needs.

“We know our customers – especially in the USA – prefer the option of combining Rapid Antigen Screening solutions and Urea Breath Testing for H. Pylori to cover a broader range of patients with specific sampling needs. Adding GCS to our portfolio truly offers the opportunity to meet our customers’ needs and help serving even more patients with gastric infections” says CEO, SSI Diagnostica Group, Christina Lindved.

Philip Ross, General Manager, GCS adds: “We are very pleased to join SSI Diagnostica Group. The combination of our product ranges allows us to provide many more product offerings to our customers, whilst we, as one group, can reach many more patients with the quality diagnostic solutions needed to mitigate the risk of H. Pylori and other infectious diseases spreading.”

About SSI Diagnostica Group

SSI Diagnostica Group is a leading global developer and manufacturer of In Vitro Diagnostic solutions for infectious diseases focused on gastric, respiratory and bloodborne conditions. Founded as a division of the renowned Statens Serum Institut, our roots go back to 1902. SSI Diagnostica was privatized in 2016 and supported by Adelis Equity Partners acquired San Diego based CTK Biotech in 2020, followed by TechLab in 2022. Techlab is a quality In Vitro Diagnostics company specialized in gastric diseases with unique products for e.g. C. Difficile and H. Pylori based out of USA, Virginia. Together, all companies now form SSI Diagnostica Group.

About Gulf Coast Scientific

Gulf Coast Scientific develops, manufactures, and distributes non-invasive diagnostic solutions for the detection of Helicobacter Pylori. Founded in 1996 in Florida, the company has a well proven record of FDA approved product ranges composed of various samplers, port analyzers, and test tubes. The company has a strong position in the American as well as international markets.

For further information or interview requests please contact: Mie Nete Petersen, Vice President Global Strategy & Corporate Development, SSI Diagnostica Group
+45 41280905, mnp@ssidiagnostica.com